Compare Albemarle Corp. (ALB) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Danaher Corporation — how do they compare? Albemarle Corp. trades at $128.4 (market cap $15.22B), while Danaher Corporation trades at $191.43 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 9× Albemarle Corp.'s market cap, and Albemarle Corp. pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| ALB | DHR | |
|---|---|---|
Market Cap | $15.22B | $137.44B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $242.05 |
52-Week Low | $67.30 | $161.91 |
Enterprise Value | $18.24B | $150.22B |
Dividend Yield | 1.26% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
